Emmanuel J Favaloro/LinkedIn
Aug 21, 2025, 14:55
Emmanuel Favaloro on DOACs Versus Warfarin in the COVID19 Era
“Did the COVID19 pandemic push the use of DOACs to the lead in the ‘anticoagulant race’, and ahead of warfarin?
Well, yes and no.
Depends on where you live. Check out this Commentary in Seminars in Thrombosis and Hemostasis.
Just released online.
Enjoy!”
Stay informed with Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026